Exoplanets that cling too tightly to their stars trigger their own doom: 'This is a completely new phenomenon'
Some planets take the expression "you're your own worst enemy" to the extreme. At least, that's what astronomers found when they recently discovered a doomed planet clinging to its parent star so tightly that it's triggering explosive outbursts and destroying itself.
The clingy, self-destructive extrasolar planet, or "exoplanet," in question is called HIP 67522 b. It orbits a young, 17 million-year-old star so closely that one of its years lasts just one Earth week.
Considering our middle-aged star, the sun, is 4.6 billion years old, the stellar parent of this clingy exoplanet (called HIP 67522) is a relative infant. This means it is bursting with energy.
Since the mid-1990s, when the first exoplanets were discovered, astronomers have pondered whether exoplanets can orbit their stars closely enough that stellar magnetic fields are impacted. Over 5,000 exoplanet discoveries later and astronomers still hadn't found the answer.
That is, until now.
"We hadn't seen any systems like HIP 67522 before; when the planet was found, it was the youngest planet known to be orbiting its host star in less than 10 days," team leader and Netherlands Institute for Radio Astronomy (ASTRON) researcher Ekaterina Ilin said in a statement. "I have a million questions because this is a completely new phenomenon, so the details are still not clear."
The team discovered HIP 67522 while using NASA's exoplanet hunting spacecraft TESS (Transiting Exoplanet Survey Satellite) to survey flaring stars.
TESS discovered some interesting characteristics of HIP 67522, prompting a follow-up investigation with the European Space Agency (ESA) mission Cheops (Characterizing Exoplanet Satellite).
"We quickly requested observing time with Cheops, which can target individual stars on demand, ultra precisely," Ilin said. "With Cheops, we saw more flares, taking the total count to 15, almost all coming in our direction as the planet transited in front of the star as seen from Earth."
Ilin and colleagues discovered that the stellar flares being thrown out by HIP 67522 occur when its clingy planet passes in front of, or "transits," the star. That means these flares are very likely triggered by the planet itself. The team theorizes this occurs because HIP 67522 b is so close to its star that it exerts a magnetic influence on the star.
As the planet whips around the star, it gathers energy, which is redirected as waves rippling down the star's magnetic field lines. When a wave hits the stellar surface, a massive flare is triggered.
"The planet seems to be triggering particularly energetic flares," Ilin explained. "The waves it sends along the star's magnetic field lines kick off flares at specific moments. But the energy of the flares is much higher than the energy of the waves.
"We think that the waves are setting off explosions that are waiting to happen."
This is therefore the first hard evidence that planets can influence the behavior of their stars.
HIP 67522 b isn't just triggering flares facing nowhere, though. These induced flares are directed toward the world itself. In particular, it is bombarded with around six times the radiation a planet at this orbital distance usually would experience.
As you might imagine, this bombardment spells doom for HIP 67522 b. The planet is currently around the size of Jupiter, but it has around the density of candy floss.
The planet's wispy outer layers are being stripped away by harsh radiation, causing the planet to lose even the little mass it has. Over the next 100 million years, HIP 67522 b is expected to drop from the size of Jupiter to around the size of Neptune. The team doesn't actually quite know how extreme the damage these self-inflicted flares could be for HIP 67522 b.
Related Stories:
— 'Vampire stars' explode after eating too much — AI could help reveal why
—Could nearby stars have habitable exoplanets? NASA's Chandra X-ray Observatory hopes to find out
—The James Webb Space Telescope has discovered its 1st exoplanet and snapped its picture (image)
"There are two things that I think are most important to do now. The first is to follow up in different wavelengths to find out what kind of energy is being released in these flares — for example, ultraviolet and X-rays are especially bad news for the exoplanet," Ilin said. "The second is to find and study other similar star-planet systems; by moving from a single case to a group of 10 to 100 systems, theoretical astronomers will have something to work with."
The team's research was published on Wednesday (July 2) in the journal Nature.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Medscape
11 minutes ago
- Medscape
Abatacept Beats HCQ in Halting RA in Palindromic Rheumatism
TOPLINE: Abatacept outperformed hydroxychloroquine (HCQ) in preventing patients with palindromic rheumatism (PR) from progressing to rheumatoid arthritis (RA). METHODOLOGY: Researchers randomly assigned 70 individuals with PR who were seropositive for rheumatoid factor or anti-citrullinated protein antibodies in a 1:1 ratio to receive open-label abatacept (ABA) at 125 mg/week or HCQ at 5 mg/kg/day for 1 year. All patients had symptom durations of over 3 months but under 3 years and were not taking any disease-modifying antirheumatic drugs or glucocorticoids. Patients were followed for an additional year to track RA development. TAKEAWAY: At month 24, three patients (8.8%) in the ABA group progressed to RA compared with 10 patients (27.8%) in the HCQ group (P = .047). Patients treated with HCQ who developed RA generally progressed in the first 12 months of the trial, whereas patients treated with ABA who developed RA did so at the end of the second year. The ABA group also had higher persistent remission rates of PR than the HCQ group (55.9% vs 22.9%). Serious adverse events were uncommon in both treatment groups. IN PRACTICE: 'In patients with recent-onset seropositive palindromic rheumatism, abatacept significantly decreased the rate of RA progression in comparison with hydroxychloroquine at 2 years follow-up,' said study author Raimon Sanmarti, MD, PhD, of the Hospital Clínic de Barcelona, Barcelona, Spain. 'Abatacept is also more efficacious than hydroxychloroquine in the control of symptoms of seropositive palindromic rheumatism.' SOURCE: Sanmarti presented the study in an oral abstract session at the European Alliance of Associations for Rheumatology (EULAR) 2025 Annual Meeting. LIMITATIONS: This was an open-label study with a relatively small sample of patients. Over the 2-year trial, eight patients in the HCQ group and five patients in the ABA group exited the trial or were lost to follow-up. DISCLOSURES: The Fundació Clínic per a la Recerca Biomèdica sponsored the study. Sanmarti disclosed financial relationships with Bristol Myers Squibb, AbbVie, MSD, Roche, UCB, Pfizer, Eli Lilly, Gebro, Janssen, Sanofi, Gilead, and Adacyte.


Medscape
an hour ago
- Medscape
Microaxial Flow Pump Reduces Heart Load in Post-MI Shock
TOPLINE: In patients with ST-segment elevation myocardial infarction (STEMI)-induced cardiogenic shock undergoing hemodynamic monitoring with a pulmonary artery catheter, the use of a microaxial flow pump (mAFP; Impella) reduced the intrinsic mechanical work performed by the heart by reducing native cardiac output and pulmonary pressures while maintaining the power output delivered to the body. METHODOLOGY: A previous Danish-German trial showed reduced mortality with early placement of an mAFP in patients with cardiogenic shock following STEMI. In this substudy, researchers analyzed data of 223 patients monitored in the cardiac ICU with a pulmonary artery catheter to determine the effects of the device on hemodynamics in STEMI-induced cardiogenic shock. Patients had been randomly assigned to receive either standard care (n = 98; median age, 67 years; 78% men) or an mAFP plus standard care (n = 125; median age, 65 years; 82% men). Outcomes included cardiac output, mean pulmonary artery pressure, and cardiac power output during the first 48 hours after admission to the cardiac ICU; native cardiac output was defined as the patient's total cardiac output minus the estimated mAFP flow. TAKEAWAY: After the initial 6 hours in the cardiac ICU, cardiac output continued to improve in the mAFP group and remained consistently higher than in the standard care group from 12 to 48 hours (P < .001). Native cardiac output also improved after 6 hours but stayed significantly lower in the mAFP group than in the standard care group. Mean pulmonary artery pressure was initially lower in the mAFP group than in the standard care group (median, 27 vs 31 mm Hg; P < .001) and remained lower at 48 hours. Pulmonary capillary wedge pressure was also lower in the patients with an mAFP. The initial cardiac power output within 3 hours of arrival to the cardiac ICU was 0.56 W in the standard care group vs 0.68 W in the mAFP group (P = .01), which improved over the next 48 hours. The mAFP group required lesser vasoactive and inotropic support than the standard care group for the first 6 hours and had lower mortality at 180 days. IN PRACTICE: 'We consistently found lower pulmonary pressures and a PCWP [pulmonary capillary wedge pressure] during mAFP support, each of which provides confirmation of LV [left ventricular] unloading while on mAFP. Reducing these pressures helps alleviate pulmonary edema, reduce right ventricular afterload, and enhance forward flow,' the researchers wrote. 'By reducing myocardial work and wall stress, unloading may be protective in stunned, postischemic myocardium vulnerable to further insult,' the authors of an editorial accompanying the journal article wrote. SOURCE: This study was led by Jacob Eifer Møller, MD, DMSc, Odense University Hospital, Odense, Denmark. It was published online on June 23, 2025, in Journal of the American College of Cardiology. LIMITATIONS: Pulmonary artery catheter was used more frequently in patients randomized to the mAFP group compared with the standard care group. Data capture may not have been streamlined or complete as this study involved patients who were critically ill, unstable, and had imminent need for treatment. Hemodynamic monitoring was limited to the first 48 hours and did not account for long-term effects or changes. DISCLOSURES: The original trial was supported by the Danish Heart Foundation and Abiomed. Several authors reported receiving research, educational, and/or travel grants, speaker fees, and honoraria; serving on advisory boards; holding stock options; and having other financial ties with various pharmaceutical, healthcare, and other companies, including Abiomed, Novo Nordisk Foundation, and Boston Scientific. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.


Medscape
an hour ago
- Medscape
Certain Plant-Based Foods May Cut Crohn's Disease Risk
TOPLINE: A high combined intake of fruits, vegetables, legumes, and potatoes was associated with a reduced risk for Crohn's disease — driven largely by specific foods such as apples or pears, bananas, mushrooms, and onions or garlic. Alternatively, a high intake of potatoes was associated with an increased risk for ulcerative colitis. METHODOLOGY: The International Organization for the Study of Inflammatory Bowel Disease recommends eating more fruits and vegetables for their fiber benefits, but current guidelines do not distinguish between subcategories despite their differing compositions and potential effects on inflammatory bowel disease (IBD) risk. Researchers analyzed data of 341,519 participants without IBD (mean age, 52.1 years; 70% women) from a popular European cohort to evaluate how consumption of individual fruits, vegetables, legumes, and potatoes influenced the risk for Crohn's disease and ulcerative colitis. At baseline, validated food frequency questionnaires were used to assess dietary intake of fruits, vegetables, legumes, and potatoes (including other tubers). Participants in the lowest vs highest quartiles had median daily intakes of 291.6 vs 840.9 g/d of combined fruits, vegetables, legumes, and potatoes; 17.0 vs 100.3 g/d of apples/pears; 6.6 vs 14.0 g/d of bananas; 2.1 vs 6.2 g/d of mushrooms; 4.1 vs 11.9 g/d of onions or garlic; and 64.7 vs 82.1 g/d of potatoes. TAKEAWAY: The median follow-up period was 13.4 years, during which 149 participants developed Crohn's disease and 379 developed ulcerative colitis. A higher combined intake of fruits, vegetables, legumes, and potatoes was associated with a lower risk of developing Crohn's disease (highest vs lowest quartile; adjusted hazard ratio [aHR], 0.44; 95% CI, 0.26-0.76) but not ulcerative colitis (aHR, 1.07; 95% CI, 0.76-1.50). A subsequent post hoc analysis showed that the pooled intake of apples or pears, bananas, mushrooms, and onions or garlic was linked to a comparable risk reduction for Crohn's disease as total fruit, vegetable, legume, and potato intake (highest vs lowest quartile; pooled aHR, 0.58; 95% CI, 0.33-1.02). However, a higher intake of potatoes was associated with a higher risk of developing ulcerative colitis (highest vs lowest quartile; aHR, 1.51; 95% CI, 1.05-2.17). IN PRACTICE: 'In conclusion, we found that high combined intake of fruits, vegetables, legumes, and potatoes is associated with a lower risk of developing CD but not UC. This was particularly apparent for apple/pear, banana, mushrooms, and onion/garlic intakes. A higher risk of UC was observed for a higher intake of potatoes,' the authors of the study wrote. SOURCE: This study was led by Antoine Meyer, MD, PhD, Université Paris-Saclay, Villejuif, France. It was published online in the American Journal of Gastroenterology. LIMITATIONS: This study relied on food frequency questionnaires measured only at baseline, which may not have fully captured dietary changes over time. The mostly older, female population may not have represented the broader European or younger populations. As with all observational studies, residual confounding from unmeasured factors could not be ruled out. DISCLOSURES: The cohort was supported by the International Agency for Research on Cancer, the Department of Epidemiology and Biostatistics, School of Public Health, and other sources. Some authors declared receiving speaker fees, grants, consulting fees, and travel support from various pharmaceutical companies. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.